Table 3.
Multivariate analysis results
| Number | RR | 95% CI lower limit | 95% CI upper limit | P-value | Overall p value | |
|---|---|---|---|---|---|---|
| Chronic GVHD | ||||||
| ATG/alemtuzumab | ||||||
| No | 174 | 1 | 0.02 | |||
| Yes | 55 | 0.58 | 0.36 | 0.93 | 0.02 | |
| Progression/Relapse | ||||||
| No significant covariates | ||||||
| Non-relapse mortality | ||||||
| No significant covariates | ||||||
| Progression-free survival | ||||||
| Disease status | ||||||
| CR | 108 | 1 | 0.03 | |||
| PR | 90 | 1.13 | 0.76 | 1.66 | 0.54 | |
| Chemoresistant | 38 | 1.73 | 1.08 | 2.77 | 0.02 | |
| Missing/Untreated | 13 | 0.43 | 0.15 | 1.20 | 0.11 | |
| Overall survival | ||||||
| Karnofsky performance score (≤ 6 months)a | ||||||
| ≥ 90% | 119 | 1 | 0.002 | |||
| < 90% | 113 | 3.46 | 1.74 | 6.87 | 0.0004 | |
| Missing | 17 | 1.95 | 0.54 | 6.98 | 0.31 | |
| Karnofsky performance score (> 6 months)a | ||||||
| ≥ 90% | 106 | 1 | 0.28 | |||
| < 90% | 80 | 0.66 | 0.39 | 1.12 | 0.12 | |
| Missing | 14 | 0.73 | 0.29 | 1.86 | 0.51 | |
GVHD graft-versus-host disease, CI confidence interval, ATG anti-thymocyte globulin, CR complete remission, PR partial remission, RR relative risk
Variables tested in the Multivariate analysis are listed in Additional file 1 Table S2
a6-months was chosen as cut-off based on the maximum likelihood value in the Cox model
p-value <0.05 is considered significant